Cargando…

Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension: randomised crossover trial

QUESTION ADDRESSED BY THE STUDY: To investigate exercise performance and hypoxia-related health effects in patients with pulmonary hypertension (PH) during a high-altitude sojourn. PATIENTS AND METHODS: In a randomised crossover trial in stable (same therapy for >4 weeks) patients with pulmonary...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Simon R., Mayer, Laura C., Lichtblau, Mona, Berlier, Charlotte, Schwarz, Esther I., Saxer, Stéphanie, Tan, Lu, Furian, Michael, Bloch, Konrad E., Ulrich, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502941/
https://www.ncbi.nlm.nih.gov/pubmed/34651040
http://dx.doi.org/10.1183/23120541.00314-2021
_version_ 1784581002405871616
author Schneider, Simon R.
Mayer, Laura C.
Lichtblau, Mona
Berlier, Charlotte
Schwarz, Esther I.
Saxer, Stéphanie
Tan, Lu
Furian, Michael
Bloch, Konrad E.
Ulrich, Silvia
author_facet Schneider, Simon R.
Mayer, Laura C.
Lichtblau, Mona
Berlier, Charlotte
Schwarz, Esther I.
Saxer, Stéphanie
Tan, Lu
Furian, Michael
Bloch, Konrad E.
Ulrich, Silvia
author_sort Schneider, Simon R.
collection PubMed
description QUESTION ADDRESSED BY THE STUDY: To investigate exercise performance and hypoxia-related health effects in patients with pulmonary hypertension (PH) during a high-altitude sojourn. PATIENTS AND METHODS: In a randomised crossover trial in stable (same therapy for >4 weeks) patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) with resting arterial oxygen tension (P(aO(2))) ≥7.3 kPa, we compared symptom-limited constant work-rate exercise test (CWRET) cycling time during a day-trip to 2500 m versus 470 m. Further outcomes were symptoms, oxygenation and echocardiography. For safety, patients with sustained hypoxaemia at altitude (peripheral oxygen saturation <80% for >30 min or <75% for >15 min) received oxygen therapy. RESULTS: 28 PAH/CTEPH patients (n=15/n=13); 13 females; mean±sd age 63±15 years were included. After >3 h at 2500 m versus 470 m, CWRET-time was reduced to 17±11 versus 24±9 min (mean difference −6, 95% CI −10 to −3), corresponding to −27.6% (−41.1 to −14.1; p<0.001), but similar Borg dyspnoea scale. At altitude, P(aO(2)) was significantly lower (7.3±0.8 versus 10.4±1.5 kPa; mean difference −3.2 kPa, 95% CI −3.6 to −2.8 kPa), whereas heart rate and tricuspid regurgitation pressure gradient (TRPG) were higher (86±18 versus 71±16 beats·min(−1), mean difference 15 beats·min(−1), 95% CI 7 to 23 beats·min(−1)) and 56±25 versus 40±15 mmHg (mean difference 17 mmHg, 95% CI 9 to 24 mmHg), respectively, and remained so until end-exercise (all p<0.001). The TRPG/cardiac output slope during exercise was similar at both altitudes. Overall, three (11%) out of 28 patients received oxygen at 2500 m due to hypoxaemia. CONCLUSION: This randomised crossover study showed that the majority of PH patients tolerate a day-trip to 2500 m well. At high versus low altitude, the mean exercise time was reduced, albeit with a high interindividual variability, and pulmonary artery pressure at rest and during exercise increased, but pressure–flow slope and dyspnoea were unchanged.
format Online
Article
Text
id pubmed-8502941
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-85029412021-10-13 Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension: randomised crossover trial Schneider, Simon R. Mayer, Laura C. Lichtblau, Mona Berlier, Charlotte Schwarz, Esther I. Saxer, Stéphanie Tan, Lu Furian, Michael Bloch, Konrad E. Ulrich, Silvia ERJ Open Res Original Research Articles QUESTION ADDRESSED BY THE STUDY: To investigate exercise performance and hypoxia-related health effects in patients with pulmonary hypertension (PH) during a high-altitude sojourn. PATIENTS AND METHODS: In a randomised crossover trial in stable (same therapy for >4 weeks) patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) with resting arterial oxygen tension (P(aO(2))) ≥7.3 kPa, we compared symptom-limited constant work-rate exercise test (CWRET) cycling time during a day-trip to 2500 m versus 470 m. Further outcomes were symptoms, oxygenation and echocardiography. For safety, patients with sustained hypoxaemia at altitude (peripheral oxygen saturation <80% for >30 min or <75% for >15 min) received oxygen therapy. RESULTS: 28 PAH/CTEPH patients (n=15/n=13); 13 females; mean±sd age 63±15 years were included. After >3 h at 2500 m versus 470 m, CWRET-time was reduced to 17±11 versus 24±9 min (mean difference −6, 95% CI −10 to −3), corresponding to −27.6% (−41.1 to −14.1; p<0.001), but similar Borg dyspnoea scale. At altitude, P(aO(2)) was significantly lower (7.3±0.8 versus 10.4±1.5 kPa; mean difference −3.2 kPa, 95% CI −3.6 to −2.8 kPa), whereas heart rate and tricuspid regurgitation pressure gradient (TRPG) were higher (86±18 versus 71±16 beats·min(−1), mean difference 15 beats·min(−1), 95% CI 7 to 23 beats·min(−1)) and 56±25 versus 40±15 mmHg (mean difference 17 mmHg, 95% CI 9 to 24 mmHg), respectively, and remained so until end-exercise (all p<0.001). The TRPG/cardiac output slope during exercise was similar at both altitudes. Overall, three (11%) out of 28 patients received oxygen at 2500 m due to hypoxaemia. CONCLUSION: This randomised crossover study showed that the majority of PH patients tolerate a day-trip to 2500 m well. At high versus low altitude, the mean exercise time was reduced, albeit with a high interindividual variability, and pulmonary artery pressure at rest and during exercise increased, but pressure–flow slope and dyspnoea were unchanged. European Respiratory Society 2021-10-11 /pmc/articles/PMC8502941/ /pubmed/34651040 http://dx.doi.org/10.1183/23120541.00314-2021 Text en Copyright ©The authors 2021 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Original Research Articles
Schneider, Simon R.
Mayer, Laura C.
Lichtblau, Mona
Berlier, Charlotte
Schwarz, Esther I.
Saxer, Stéphanie
Tan, Lu
Furian, Michael
Bloch, Konrad E.
Ulrich, Silvia
Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension: randomised crossover trial
title Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension: randomised crossover trial
title_full Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension: randomised crossover trial
title_fullStr Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension: randomised crossover trial
title_full_unstemmed Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension: randomised crossover trial
title_short Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension: randomised crossover trial
title_sort effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension: randomised crossover trial
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502941/
https://www.ncbi.nlm.nih.gov/pubmed/34651040
http://dx.doi.org/10.1183/23120541.00314-2021
work_keys_str_mv AT schneidersimonr effectofadaytriptoaltitude2500monexerciseperformanceinpulmonaryhypertensionrandomisedcrossovertrial
AT mayerlaurac effectofadaytriptoaltitude2500monexerciseperformanceinpulmonaryhypertensionrandomisedcrossovertrial
AT lichtblaumona effectofadaytriptoaltitude2500monexerciseperformanceinpulmonaryhypertensionrandomisedcrossovertrial
AT berliercharlotte effectofadaytriptoaltitude2500monexerciseperformanceinpulmonaryhypertensionrandomisedcrossovertrial
AT schwarzestheri effectofadaytriptoaltitude2500monexerciseperformanceinpulmonaryhypertensionrandomisedcrossovertrial
AT saxerstephanie effectofadaytriptoaltitude2500monexerciseperformanceinpulmonaryhypertensionrandomisedcrossovertrial
AT tanlu effectofadaytriptoaltitude2500monexerciseperformanceinpulmonaryhypertensionrandomisedcrossovertrial
AT furianmichael effectofadaytriptoaltitude2500monexerciseperformanceinpulmonaryhypertensionrandomisedcrossovertrial
AT blochkonrade effectofadaytriptoaltitude2500monexerciseperformanceinpulmonaryhypertensionrandomisedcrossovertrial
AT ulrichsilvia effectofadaytriptoaltitude2500monexerciseperformanceinpulmonaryhypertensionrandomisedcrossovertrial